Kerry Chester, PhDProfessor of Molecular Medicine at UCL Cancer Institute
Kerry Chester is a Professor of Molecular Medicine at UCL and the CSO of NovalGen. She has over 25 years’ experience in antibody engineering and phage-display technology. Kerry has established academic GMP manufacturing for Phase I Trials and led development of novel antibodies for use as cancer imaging agents, recombinant antibody-enzyme fusion proteins, antibody drug conjugates and chimeric antigen receptors. She obtained her PhD from the University of London where she studied human antibody responses to cancer and she developed phage technology skills in Sir Greg Winter’s laboratory at Cambridge. Kerry is on the Board of Directors of The Antibody Society.